ID | 62388 |
フルテキストURL | |
著者 |
Obata, Kyoichi
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Okui, Tatsuo
Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine
Ono, Sawako
Department of Pathology, Kagawa Prefectural Central Hospital
Umemori, Koki
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ryumon, Shoji
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ono, Kisho
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Yao, Mayumi
Department of Dentistry and Dental Surgery, Tsuyama Chuo Hospital
Yoshioka, Norie
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Ibaragi, Soichiro
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Sasaki, Akira
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
|
抄録 | Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is an iatrogenic immunodeficiency-associated lymphoproliferative disorder that occurs mainly with MTX use. This disorder has been associated with Epstein-Barr virus (EBV) infection. In 2017, the WHO newly defined the disease concept of EBV-positive mucocutaneous ulcer (EBV-MCU) as a good-prognosis EBV-related disease. Here, we report 10 cases of MTX-LPD or EBV-MCU in the oral mucosa. This retrospective, observational study was conducted with MTX-LPD or EBV-MCU in the oral mucosa patients who visited us during the nine year period from 2012 to 2021. We gathered the basic information, underlying disease, histopathological evaluation, treatment and prognosis for the subjects. All were being treated with MTX for rheumatoid arthritis. EBV infection was positive in all cases by immunohistochemistry. A complete or partial response was obtained in all cases with the withdrawal of MTX. Our results suggests that the most common risk factor for developing EBV-MCU is the use of immunosuppressive drugs. The most common site of onset is the oral mucosa, which may be attributed to the mode of EBV infection and the high incidence of chronic irritation of the oral mucosa. A small number of patients had been diagnosed with MTX-LPD, but we consider that these cases were EBV-MCU based on our study.
|
キーワード | methotrexate
lymphoproliferative disorders
Epstein-Barr virus
mucocutaneous ulcer
rheumatoid arthritis
|
発行日 | 2021-07-30
|
出版物タイトル |
Diagnostics
|
巻 | 11巻
|
号 | 8号
|
出版者 | MDPI
|
開始ページ | 1375
|
ISSN | 2075-4418
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2021 by the authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.3390/diagnostics11081375
|
ライセンス | https://creativecommons.org/licenses/by/4.0/
|
助成機関名 |
Japan Society for the Promotion of Science
|
助成番号 | 20K18668
|
オープンアクセス(出版社) |
OA
|